-+ 0.00%
-+ 0.00%
-+ 0.00%

ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES IND SUBMISSION TO U.S. FDA FOR ISB 2301, A FIRST-IN-CLASS MULTISPECIFIC IMMUNE CELL ACTIVATOR TARGETING SOLID TUMORS

Reuters·11/17/2026 14:14:49

Please log in to view news